{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-200535","form_type":"8-K","ticker":"MDXG","cik":"0001376339","company_name":"MIMEDX GROUP, INC.","filed_at":"2023-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.738807+00:00","generated_at":"2026-06-12T17:31:17.836752+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MiMedx Q2 net sales $81.3M (+21.5% YoY); raises FY2023 growth guidance to mid-to-high teens","bullets":["Net sales $81.3M (+21.5% YoY); net income $1.2M; Adj. EBITDA $14.1M (17.4% of sales).","Raises full-year 2023 net sales growth guidance to mid-to-high teens.","Appoints Doug Rice as CFO, rounding out executive team.","Reports favorable appellate ruling affirming dismissal of securities class action.","Announced strategic realignment focusing on Wound & Surgical businesses to improve profitability."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-200535","json":"https://secwatch.observer/filing/0001193125-23-200535.json","markdown":"https://secwatch.observer/filing/0001193125-23-200535.md","text":"https://secwatch.observer/filing/0001193125-23-200535.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1376339/000119312523200535/0001193125-23-200535-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1376339/000119312523200535/d472149d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T17:31:17.836752+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b684bafcd3246d8f015e5dba616c3a3caac1c180","claim":"MIMEDX GROUP, INC. reported second quarter ended June 30, 2023 results: revenue $81.3 million, net income $1.2 million. Guidance raised.","evidence_excerpt":"report on Form 8-K. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 MIMEDX Announces Second Quarter 2023 Operating and Financial Results Records Second Quarter Net Sales of $81.3 Million; an Increase of 21.5% Over the Prior Year Period Increases Full-Year 2023 Guidance for Net Sales Growth Welcomes Highly Successful MedTech Executive as Chief Financial Officer","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1376339/000119312523200535/0001193125-23-200535-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$81.3 million"},{"label":"Net income","value":"$1.2 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}